Our analysis of an ovarian cancer cohort stratified by resistance or responsiveness to bevacizumab-based therapy demonstrated a correlation between the overexpression of CD5L in tumor endothelial cells and bevacizumab resistance. This evidence concerns the gene CD5L and neoplasm.